Use of Prior Information to Stabilize a Population Data Analysis

When modeling new data with a complex population pharmacokinetic/pharmacodynamic model, there may not be sufficient information to obtain estimates of all parameters. In this case information from previous studies can also be used to help stabilize estimation. Using simulated data, we explored three different ways to do this. (i) Some parameter values were fixed to estimates obtained from earlier data. (ii) The earlier data were combined with the current data. (iii) The objective function based on the current data was augmented by a penalty function expressing summary information obtained from the earlier data. This last method is similar to the use of a Bayesian prior. It may be particularly useful when either the combined data set of method (ii) is very large and leads to large computation times or when the early data are not readily available. With this method, two different types of penalty functions were used. With our examples, the three methods all resulted in stabilized estimation. Methods (ii) and (iii) gave similar results for parameter and standard error estimation, especially with respect to fixed effects parameters. For hypothesis testing, results obtained with method (i) are very problematic. There are also problems with the results obtained with method (iii), but they are much less severe, and when the design for the earlier data is known, they can be corrected by using a computer-intensive simulation test procedure.

[1]  J. Wakefield The Bayesian Analysis of Population Pharmacokinetic Models , 1996 .

[2]  Aaron Tucker,et al.  A Bibliography. , 1902, British medical journal.

[3]  Model Building and Validation : Contributions of the Taguchi Method , 1998 .

[4]  Gelfand,et al.  AD-A 254 769 BAYESIAN ANALYSIS OF LINEAR AND NONLINEAR POPULATION MODELS USING THE GIBBS SAMPLER , 2022 .

[5]  Stuart L. Beal,et al.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  Adrian F. M. Smith,et al.  Bayesian Analysis of Linear and Non‐Linear Population Models by Using the Gibbs Sampler , 1994 .

[7]  M. Kendall Theoretical Statistics , 1956, Nature.

[8]  Lewis B. Sheiner,et al.  A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  Mats O. Karlsson,et al.  Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[10]  W. R. Buckland,et al.  Distributions in Statistics: Continuous Multivariate Distributions , 1973 .

[11]  Stuart L. Beal,et al.  Commentary on Significance Levels for Covariate Effects in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  L. Sheiner,et al.  Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  J. Wade,et al.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[14]  M. Karlsson,et al.  Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats. , 2000, Anticancer Research.

[15]  T. Ludden,et al.  Application of population analysis to physiological pharmacokinetics , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[17]  M Davidian,et al.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. , 1994, Biometrics.

[18]  G. C. Tiao,et al.  Bayesian inference in statistical analysis , 1973 .